Biotica is positioning to be a world-class research and development facility in endocannabinoid drug development. Biotica has set-up a state-of-the-art research and development lab to enhance the BPRxTM platform and rapidly expanding its research capabilities. Biotica’s research includes specific programs for eosinophilic esophagitis, Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our therapies will use a BPRxTM platform to optimize the synergistic combination of phytocannabinoids and endocannabinoids to modulate disease pathology and progression. By significantly decreasing the production of relevant signalling and causative molecules at targeted sites within various tissue systems, the goal is to address the underlying biology of the disease and make a meaningful difference for patients. Our talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.